Related Experiment Video

Updated: Jun 6, 2026

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

Fungal sepsis: optimizing antifungal therapy in the critical care setting

Alexander Lepak1, David Andes

  • 1University of Wisconsin, MFCB, Room 5218, 1685 Highland Avenue, Madison, WI 53705-2281, USA.

Critical Care Clinics
|December 15, 2010
PubMed

Insights

Invasive fungal infections (IFI) in intensive care units are rising, primarily from Candida. Early diagnosis and prompt antifungal treatment are crucial for improving patient outcomes and reducing mortality.

Area of Science:

  • Critical care medicine
  • Mycology
  • Infectious diseases

Background:

  • Invasive fungal infections (IFI) and fungal sepsis are increasing in intensive care units (ICUs).
  • These infections, predominantly caused by Candida species, are linked to significant patient morbidity and mortality.
  • Current outcomes for IFI in ICUs remain suboptimal.

Purpose of the Study:

  • To highlight key clinician-modifiable factors influencing outcomes in ICU fungal infections.
  • To emphasize the importance of pharmacokinetics-pharmacodynamics (PK-PD) and timely treatment.
  • To underscore the need for advancements in early recognition and source control.

Main Methods:

  • Review of existing literature on antifungal PK-PD.
  • Analysis of factors influencing outcomes in invasive candidiasis.
  • Discussion of diagnostic and therapeutic strategies in critical care settings.

Main Results:

  • PK-PD studies offer guidance on optimal dosing strategies for antifungal agents.
  • Time to initiation of antifungal therapy is a critical determinant of patient outcome.
  • Early recognition via improved risk factor analysis and diagnostics are essential developments.

Conclusions:

  • Optimizing antifungal dosing based on PK-PD principles can improve outcomes.
  • Reducing the time to effective therapy is paramount for managing invasive fungal infections.
  • Enhanced diagnostic tools and prompt source control are vital for improving survival rates in ICU patients with fungal sepsis.

More Related Videos

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: